EUROAPI Reaches Major Health IPCEI Milestone with Official Notification from European Commission

Paris – June 6, 2024 – EUROAPI has received an official notification from the European Commission, confirming the company's selection as one of the 13 firms eligible to share up to EUR 1 billion under the Important Project of Common European Interest (IPCEI) dedicated to the pharmaceutical sector, “IPCEI Med4Cure”.

Jointly notified by six EU Member States—France, Belgium, Hungary, Italy, Slovakia, and Spain—this initiative aims to fortify the European health market and boost sustainable, competitive production of crucial active pharmaceutical ingredients (APIs). The EU has authorized the allocation of up to EUR 1 billion in public funds for selected projects under this program.

EUROAPI aims to leverage this opportunity to develop three key programs in Europe. The initiatives include reshoring macrolide antibiotics production at the Saint-Aubin-lès-Elbeuf site, advancing corticosteroids production processes at the Vertolaye site, and enhancing nanoparticle technologies for better drug delivery and bioavailability.

CEO Ludwig de Mot expressed pride over this achievement, highlighting that it underscores the company’s mission and excellence in R&D, while also supporting long-term European sovereignty and the pharmaceutical sector’s green transition.